PE20120898A1 - Inhibidores de dihidroorotato deshidrogenasa como compuestos virostaticos - Google Patents
Inhibidores de dihidroorotato deshidrogenasa como compuestos virostaticosInfo
- Publication number
- PE20120898A1 PE20120898A1 PE2011001900A PE2011001900A PE20120898A1 PE 20120898 A1 PE20120898 A1 PE 20120898A1 PE 2011001900 A PE2011001900 A PE 2011001900A PE 2011001900 A PE2011001900 A PE 2011001900A PE 20120898 A1 PE20120898 A1 PE 20120898A1
- Authority
- PE
- Peru
- Prior art keywords
- alkanyl
- alkinyl
- alkenyl
- aryl
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 title 1
- 230000001790 virustatic effect Effects 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: A ES UN ANILLO HIDROCARBONADO AROMATICO O NO AROMATICO C5-C6 DONDE OPCIONALMENTE UNO O MAS ATOMOS DE CARBONO SE REEMPLAZAN POR UN GRUPO X; L ES UNA UNION SIMPLE, NH; D ES O, S, SO2, NR4, CH2; Z1 Y Z2 SON CADA UNO O, S, NR5; R1 ES H, HALOGENO, HALOALCANILO, HALOALQUENILO, ENTRE OTROS; R2 ES H, NH2, OH, ENTRE OTROS; R3 ES H, ALCANILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS; R4 ES H, ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R5 ES H, HO, ALCANILOXI, ALQUENILOXI, O-ARILO, ALCANILO, ENTRE OTROS; R8 ES H, ALCANILLO, ALQUENILO O ALQUINILO; X ES S, O, N, NR4, SO2, SO; Y ES H, HALOGENO, HALOALCANILO, HALOALCANILOXI, ENTRE OTROS; E ES ARILO, HETEROARILO, ALQUENILO, ALQUINILO O UN SISTEMA DE ANILLOS FUSIONADOS BICICLICO O TRICICLICO; m, n, q Y r SON CADA 0-1; t ES 0-3.UN COMPUESTO PREFERIDO ES ACIDO 3-(2,3,5,6-TETRAFLUORO-3'-TRIFLUOROMETOXI-BIFENIL-4-ILCARBAMOIL)-TIOFEN-3-CARBOXILICO. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN INHIBIDOR DE DIHIDROORATO DESHIDROGENASA UTILIZADO PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES VIRALES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17552209P | 2009-05-04 | 2009-05-04 | |
| EP09159358 | 2009-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120898A1 true PE20120898A1 (es) | 2012-08-24 |
Family
ID=43030861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001900A PE20120898A1 (es) | 2009-05-04 | 2010-05-04 | Inhibidores de dihidroorotato deshidrogenasa como compuestos virostaticos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8354433B2 (es) |
| EP (1) | EP2427186B1 (es) |
| CN (1) | CN102458389A (es) |
| AR (1) | AR076837A1 (es) |
| AU (1) | AU2010244462B2 (es) |
| CA (1) | CA2761130C (es) |
| CO (1) | CO6450622A2 (es) |
| ES (1) | ES2909738T3 (es) |
| MX (1) | MX2011011733A (es) |
| NZ (1) | NZ596014A (es) |
| PE (1) | PE20120898A1 (es) |
| SG (1) | SG175854A1 (es) |
| TW (1) | TWI530286B (es) |
| UY (1) | UY32605A (es) |
| WO (1) | WO2010128050A2 (es) |
| ZA (1) | ZA201108131B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108760C2 (uk) * | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
| US9296719B2 (en) * | 2011-07-08 | 2016-03-29 | Indiana University Research And Technology Corporation | Compositions and methods for the treatment of norovirus infection |
| AU2014390300A1 (en) | 2014-04-11 | 2016-10-20 | Panoptes Pharma Gmbh | Anti-inflammatory agents as virostatic compounds |
| JP6629840B2 (ja) | 2014-05-08 | 2020-01-15 | パノプテス・ファーマ・ゲーエムベーハー | 眼の疾患および障害を処置するための化合物 |
| TW201834649A (zh) | 2017-03-02 | 2018-10-01 | 新加坡商亞獅康私人有限公司 | 癌症療法 |
| BR112020017988A2 (pt) | 2018-03-09 | 2020-12-22 | Panoptes Pharma Ges.M.B.H. | Composição oftálmica |
| US20220227720A1 (en) * | 2019-05-07 | 2022-07-21 | Universitat Hamburg | Dhodh inhibitors and their use as antiviral agents |
| US11376232B2 (en) * | 2020-04-21 | 2022-07-05 | Immunic Ag | Vidofludimus for use in the treatment or prevention of viral diseases |
| EP4203953A1 (en) * | 2020-08-31 | 2023-07-05 | ASLAN Pharmaceuticals Pte Ltd | Treatment and/or prevention of a viral infection |
| JPWO2022196236A1 (es) * | 2021-03-18 | 2022-09-22 | ||
| US20240199535A1 (en) | 2021-04-09 | 2024-06-20 | Immunic Ag | Deuterated dhodh inhibitors |
| EP4119138A1 (en) * | 2021-07-12 | 2023-01-18 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
| JP2025500176A (ja) | 2021-12-23 | 2025-01-09 | イミュニック アクチェンゲゼルシャフト | カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤 |
| CA3245254A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
| CA3245493A1 (en) | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR |
| IL317127A (en) | 2022-06-01 | 2025-01-01 | Immunic Ag | Ulcerative colitis treatment containing vidoplodimes or its pharmaceutical salt |
| TW202506107A (zh) | 2023-06-28 | 2025-02-16 | 德商埃慕尼克股份公司 | 雜芳族dhodh抑制劑 |
| CN116803387A (zh) * | 2023-07-25 | 2023-09-26 | 徐州医科大学 | Vidofludimus在制备戊型肝炎药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19860802A1 (de) * | 1998-12-30 | 2000-10-26 | Virgene Pharmaceuticals Ag | Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren |
| AU7622000A (en) * | 1999-10-01 | 2001-05-10 | Institute Of Molecular And Cell Biology | Compounds for the treatment of viral-mediated diseases |
| WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| BR0317687A (pt) * | 2002-12-23 | 2005-11-22 | 4Sc Ag | Compostos aromáticos como agentes antiinflamatórios, imunomoduladores e antiproliferativos |
| WO2004056747A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| US7071355B2 (en) * | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2010
- 2010-04-30 TW TW099113936A patent/TWI530286B/zh not_active IP Right Cessation
- 2010-05-03 UY UY0001032605A patent/UY32605A/es not_active Application Discontinuation
- 2010-05-03 US US12/772,470 patent/US8354433B2/en active Active
- 2010-05-04 PE PE2011001900A patent/PE20120898A1/es not_active Application Discontinuation
- 2010-05-04 AR ARP100101509A patent/AR076837A1/es unknown
- 2010-05-04 WO PCT/EP2010/056042 patent/WO2010128050A2/en not_active Ceased
- 2010-05-04 EP EP10715894.1A patent/EP2427186B1/en active Active
- 2010-05-04 CA CA2761130A patent/CA2761130C/en not_active Expired - Fee Related
- 2010-05-04 AU AU2010244462A patent/AU2010244462B2/en not_active Ceased
- 2010-05-04 CN CN2010800290606A patent/CN102458389A/zh active Pending
- 2010-05-04 MX MX2011011733A patent/MX2011011733A/es active IP Right Grant
- 2010-05-04 SG SG2011080488A patent/SG175854A1/en unknown
- 2010-05-04 ES ES10715894T patent/ES2909738T3/es active Active
- 2010-05-04 NZ NZ596014A patent/NZ596014A/xx not_active IP Right Cessation
-
2011
- 2011-11-03 ZA ZA2011/08131A patent/ZA201108131B/en unknown
- 2011-11-04 CO CO11150236A patent/CO6450622A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8354433B2 (en) | 2013-01-15 |
| UY32605A (es) | 2010-12-31 |
| US20100280081A1 (en) | 2010-11-04 |
| EP2427186A2 (en) | 2012-03-14 |
| CA2761130C (en) | 2017-03-28 |
| MX2011011733A (es) | 2012-02-01 |
| ES2909738T3 (es) | 2022-05-10 |
| WO2010128050A3 (en) | 2011-05-05 |
| CO6450622A2 (es) | 2012-05-31 |
| EP2427186B1 (en) | 2022-01-12 |
| CA2761130A1 (en) | 2010-11-11 |
| TW201043228A (en) | 2010-12-16 |
| TWI530286B (zh) | 2016-04-21 |
| AR076837A1 (es) | 2011-07-13 |
| ZA201108131B (en) | 2012-07-25 |
| AU2010244462B2 (en) | 2015-07-02 |
| AU2010244462A1 (en) | 2011-11-17 |
| WO2010128050A2 (en) | 2010-11-11 |
| CN102458389A (zh) | 2012-05-16 |
| SG175854A1 (en) | 2011-12-29 |
| NZ596014A (en) | 2013-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120898A1 (es) | Inhibidores de dihidroorotato deshidrogenasa como compuestos virostaticos | |
| EA201290089A1 (ru) | Химические соединения | |
| SA521431048B1 (ar) | مركبات بيروليدين | |
| EA201270560A1 (ru) | Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета | |
| ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| CO6382126A2 (es) | Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas | |
| EA201290416A1 (ru) | Новые спиропиперидиновые соединения | |
| ATE555105T1 (de) | Heterocyclische fxr-bindende verbindungen | |
| AR062149A1 (es) | Un proceso para la preparacion de intermediarios opticamente activos | |
| PH12015501881B1 (en) | Amide compounds for the treatment of hiv | |
| EA201071202A1 (ru) | Индолы в качестве модуляторов никотинового рецептора ацетилхолина подтипа альфа-7 | |
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| MA31889B1 (fr) | N-phenyl -bipyrrolidine-urees substituees et utilisation therapeutique de celles-ci | |
| EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине | |
| BR112013000248A2 (pt) | derivados de dióxido de 1,3-propano espirociclicamente substituído, método para a produção dos mesmos e uso dos mesmos como medicamento | |
| BR112014010401A8 (pt) | Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| EA201190293A1 (ru) | Пролекарства триптолида | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EA201792072A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| PE20150021A1 (es) | 5-amino[1,4]tiazinas como inhibidores de bace1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |